Active Biotech has received an indicative bid for the property in Lund - the Board is positive
February 01 2019 - 10:15AM
As previously reported, Active
Biotech's property Forskaren 1 in Lund has been on sale for a
period of time. Active Biotech has now received an indicative,
non-binding bid for the property, amounting to SEK 275 million from
a newly formed investor collective led by the real estate company
Estea AB (Estea). The bid corresponds to the property's book value.
Active Biotech's Board is in favor of the bid.
The indicative bid is conditional
to a successful due diligence process carried out by Estea. No
sales agreement has been concluded, and it is not certain that such
agreement will be reached, or what the terms for a possible sale of
the property will be. Estea will carry out the due diligence
process and secure financing during a maximum period of one
month.
Active Biotech's largest
shareholder, MGA Holding AB (Mats Arnhög), has, on the request of
Estea, declared its willingness to participate, with a
maximum of 40 percent, to be determined by Estea, of Estea's equity
financing. If an agreement with Estea, for the sale of the property
is met, the Board's intention is to call for an extraordinary
general meeting to let the shareholders decide on the sale.
Lund February 1, 2019
Helèn Tuvesson
President & CEO
For further information, please
contact:
Hans Kolam, CFO
Tel +46 46 19 20 44
Active Biotech AB (publ)
(NASDAQ Stockholm: ACTI) is a biotechnology company with focus on
neurodegenerative/inflammatory diseases and cancer. Laquinimod, an
orally administered small molecule with unique immunomodulatory
properties in development for neurodegenerative diseases. ANYARA,
an immunotherapy, in development for cancer indications in
partnership with NeoTX Therapeutics Ltd. Furthermore, commercial
activities are conducted for the tasquinimod, paquinimod and SILC
projects. Please visit www.activebiotech.com for more
information.
Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46 19 20 00
This information is information
that Active Biotech AB is obliged to make public pursuant to the EU
Market Abuse Regulation. This information was submitted for
publication, through the agency of the contact person set out
above, at 16.15 a.m. CET
on February 1, 2019.
Active Biotech has received an
indicative bid for the property
This
announcement is distributed by West Corporation on behalf of West
Corporation clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Active Biotech via Globenewswire
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Apr 2023 to Apr 2024